News & Trends - MedTech & Diagnostics
Siemens’ cutting-edge imaging system to benefit cardiology patients

Royal Perth Hospital (RPH) has become the first hospital in Western Australia to boast Siemens’ new generation imaging system for patients undergoing specialised cardiac procedures.
It is one of less than 50 in hospitals across the world to invest in the Siemens’ ‘ARTIS Icono system’.
Each year, RPH conducts more than 4,500 cardiac procedures. The system will provide improved patient outcomes through superior imaging and greater efficiency during cardiac procedures.
Medical imaging in a catheterisation laboratory (‘cath lab’) helps guide cardiologists as they perform procedures, including lifesaving angioplasty and stent implants for the treatment of heart attacks, pacemaker and other device implants to correct heart arrhythmias and a range of other specialised cardiac procedures.
The new cutting-edge technology is a long-term investment by the McGowan Government to help ensure patients and staff have access to the latest in technology to support the delivery of world class medical care.
Health Minister Roger Cook said “This is an example of the innovative important work taking place across the WA health system and will make an enormous contribution to our patients undergoing important cardiac procedures. It is essential to ensure our hospitals are using modern and effective technology to complete important tests and procedures and review in a timely manner because it improves patient outcomes.”
Key design features of the new system include superior image quality and procedural intelligence allowing patients to receive more accurate results, faster. This state-of-the-art system also allows cardiologists to make decisions faster and more accurately during time-critical procedures, such as serious heart attacks.
News & Trends - Pharmaceuticals

Clinicians shift stance, join calls for PBS subsidy of obesity and weight-loss medicines
Over a third of Australian adults live with obesity, and the National Obesity Strategy estimates the direct and indirect costs […]
MoreNews & Trends - Pharmaceuticals

Astellas secures new indication for prostate cancer drug
Astellas Xtandi (enzalutamide) is now TGA registered for a new indication for patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with […]
MoreNews & Trends - MedTech & Diagnostics

Stakeholder calls intensify as government stalls on genetic discrimination ban
Calls have intensified for the federal government to honour its commitment to outlaw genetic discrimination in life insurance, as stakeholders […]
MoreNews & Trends - MedTech & Diagnostics

Pressure mounts to expand home-based therapies in kidney disease: World Kidney Day
As Australia marks World Kidney Day, the stark reality is that one in three adults is at risk of chronic […]
More